Smith & Nephew plc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB0009223206
GBP
12.31
-0.03 (-0.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.26 M

Shareholding (Jun 2024)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 22.98%

 
2

Poor long term growth as Operating profit has grown by an annual rate 3.16% of over the last 5 years

 
3

Flat results in Jun 25

4

With ROE of 9.45%, it has a expensive valuation with a 2.90 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 10,467 Million (Large Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

590.13%

stock-summary
Debt Equity

0.48

stock-summary
Return on Equity

9.45%

stock-summary
Price to Book

2.59

Revenue and Profits:
Net Sales:
789 Million
(Quarterly Results - Dec 2014)
Net Profit:
101 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.34%
0%
-11.34%
6 Months
13.82%
0%
13.82%
1 Year
23.74%
0%
23.74%
2 Years
18.93%
0%
18.93%
3 Years
13.03%
0%
13.03%
4 Years
0.12%
0%
0.12%
5 Years
-17.43%
0%
-17.43%

Smith & Nephew plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.08%
EBIT Growth (5y)
3.16%
EBIT to Interest (avg)
67.31
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.43
Tax Ratio
29.67%
Dividend Payout Ratio
78.32%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
22.98%
ROE (avg)
18.53%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
2.90
EV to EBIT
23.51
EV to EBITDA
16.24
EV to Capital Employed
2.29
EV to Sales
4.86
PEG Ratio
NA
Dividend Yield
765.22%
ROCE (Latest)
9.73%
ROE (Latest)
9.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'14 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2014 is 8.69% vs 8.23% in Dec 2013",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2014 is 1.00% vs 13.24% in Dec 2013",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'14",
        "Dec'13",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "789.00",
          "val2": "725.90",
          "chgp": "8.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "273.50",
          "val2": "219.30",
          "chgp": "24.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "13.30",
          "val2": "1.90",
          "chgp": "600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-36.60",
          "val2": "-21.00",
          "chgp": "-74.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "101.10",
          "val2": "100.10",
          "chgp": "1.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "251.40%",
          "val2": "228.90%",
          "chgp": "2.25%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.85% vs 5.44% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.36% vs 16.91% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,546.80",
          "val2": "4,464.00",
          "chgp": "1.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,196.60",
          "val2": "1,177.70",
          "chgp": "1.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "117.40",
          "val2": "106.20",
          "chgp": "10.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-230.90",
          "val2": "-397.40",
          "chgp": "41.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "322.40",
          "val2": "211.60",
          "chgp": "52.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "167.60%",
          "val2": "168.90%",
          "chgp": "-0.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'14 - YoYstock-summary
Dec'14
Dec'13
Change(%)
Net Sales
789.00
725.90
8.69%
Operating Profit (PBDIT) excl Other Income
273.50
219.30
24.72%
Interest
13.30
1.90
600.00%
Exceptional Items
-36.60
-21.00
-74.29%
Consolidate Net Profit
101.10
100.10
1.00%
Operating Profit Margin (Excl OI)
251.40%
228.90%
2.25%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2014 is 8.69% vs 8.23% in Dec 2013

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2014 is 1.00% vs 13.24% in Dec 2013

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4,546.80
4,464.00
1.85%
Operating Profit (PBDIT) excl Other Income
1,196.60
1,177.70
1.60%
Interest
117.40
106.20
10.55%
Exceptional Items
-230.90
-397.40
41.90%
Consolidate Net Profit
322.40
211.60
52.36%
Operating Profit Margin (Excl OI)
167.60%
168.90%
-0.13%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1.85% vs 5.44% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 52.36% vs 16.91% in Dec 2023

stock-summaryCompany CV
About Smith & Nephew plc stock-summary
stock-summary
Smith & Nephew plc
Pharmaceuticals & Biotechnology
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Company Coordinates stock-summary
Company Details
Building 5, Croxley Park, Hatters Lane , WATFORD None : WD18 8YE
stock-summary
Tel: 44 20 7401764644 20 79602285
stock-summary
Registrar Details